OLD National Bancorp IN Reduces Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Posted by on Apr 24th, 2023

OLD National Bancorp IN lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 34.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,445 shares of the company’s stock after selling 9,173 shares during the period. OLD National Bancorp IN’s holdings in Axsome Therapeutics were worth $1,345,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. PFM Health Sciences LP boosted its position in Axsome Therapeutics by 22.0% in the third quarter. PFM Health Sciences LP now owns 1,659,733 shares of the company’s stock valued at $74,057,000 after buying an additional 299,137 shares during the last quarter. Brinker Capital Investments LLC purchased a new stake in Axsome Therapeutics in the 3rd quarter worth approximately $267,000. Creative Planning purchased a new stake in Axsome Therapeutics in the 3rd quarter worth approximately $411,000. Legato Capital Management LLC purchased a new stake in Axsome Therapeutics in the 4th quarter worth approximately $542,000. Finally, Tower Research Capital LLC TRC boosted its position in Axsome Therapeutics by 1,928.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 26,291 shares of the company’s stock worth $1,173,000 after purchasing an additional 24,995 shares in the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Morgan Stanley lowered their price objective on Axsome Therapeutics from $85.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 12th. Guggenheim reduced their target price on Axsome Therapeutics from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Axsome Therapeutics in a research note on Monday, April 17th. Bank of America reaffirmed an “underperform” rating and set a $52.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, February 14th. Finally, StockNews.com assumed coverage on Axsome Therapeutics in a research note on Thursday, March 16th. They set a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $103.79.

Axsome Therapeutics Stock Up 2.3 %

NASDAQ AXSM opened at $72.92 on Monday. The business has a fifty day moving average price of $63.88 and a 200 day moving average price of $63.54. Axsome Therapeutics, Inc. has a one year low of $20.63 and a one year high of $82.00. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.50 and a current ratio of 2.54. The company has a market cap of $3.17 billion, a P/E ratio of -15.96 and a beta of 1.89.

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last issued its earnings results on Monday, February 27th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.10). The business had revenue of $24.37 million during the quarter, compared to analyst estimates of $21.51 million. Research analysts anticipate that Axsome Therapeutics, Inc. will post -4.3 EPS for the current fiscal year.

About Axsome Therapeutics

(Get Rating)

Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14.

See Also

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.